

June 25, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir/Madam,

Sub: Withdrawal of applications for EU Marketing Authorisations – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

M/s. CuraTeQ Biologics s.r.o.'s, a wholly owned step-down subsidiary of the Company, request to withdraw the applications for Marketing Authorization of ZEFYLT (a filgrastim biosimilar) and DYRUPEG (a peg-filgrastim biosimilar) has been accepted by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA as we will not be able to obtain EU-GMP certification of our biosimilars manufacturing facility within the current Day 180 clock stop period and no further clock-stop extensions would be possible at this stage of the review procedure by CHMP. We will be working with the Agency to re-submit these applications at the earliest.

We wish to reiterate that this withdrawal is procedural in nature and does not impact any future filings and/or on-going clinical studies. It is our intent to seek re-submission of these filings for Marketing Authorisation with EMA at the earliest.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H